Metabolic syndrome and population attributable risk among HIV/AIDS patients: comparison between NCEP-ATPIII, IDF and AHA/NHLBI definitions

AIDS Research and Therapy

Paulo R Alencastro⁴  Fernando H Wolff³  Renato R Oliveira⁵  Maria Letícia R Ikeda¹  Nêmora T Barcellos³  Ajácio B M Brandão⁴  Sandra C Fuchs² 

[1] Postgraduate Studies Program in Cardiology, School of Medicine, Universidade Federal do Rio Grande do Sul, R. Ramiro Barcelos 2600, Porto Alegre, RS, CEP 90035-003, Brazil

[2] Centro de Pesquisa Clínica Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Ramiro Barcellos, 2350, 5° andar 90.035-000, Porto Alegre, RS, Brazil

[3] Postgraduate Studies Program in Epidemiology, School of Medicine, Universidade Federal do Rio Grande do Sul, R. Ramiro Barcelos 2600, Porto Alegre, RS, CEP 90035-003, Brazil

[4] National Institute for Science and Technology for Health Technology Assessment (IATS/CNPq), Hospital de Clínicas de Porto Alegre. R. Ramiro Barcelos 2350, Centro de Pesquisas, Cardiolab-Hipertensão, Porto Alegre, RS, CEP 90035-003, Brazil

[5] Hospital Sanatório Partenon, Health Secretariat of State of Rio Grande do Sul, Av. Bento Goncalves, 3722, Porto Alegre, RS, CEP: 90650-001, Brazil

关键词: Waist circumference;    AHA/NHLBI;    IDF;    NCEP-ATPIII;    HIV/AIDS;    Population attributable risk;    Metabolic syndrome;   

Others  :  789637
DOI  :  10.1186/1742-6405-9-29

 received in 2012-08-12, accepted in 2012-10-02,  发布年份 2012

【 摘 要 】

Background

Metabolic Syndrome (MetS) is based on the same individual components, but has received several amendments to the original definition. In this study, we verified the prevalence of metabolic syndrome according to different criteria, and the impact of each component on the diagnostic.

Methods

This cross-sectional study enrolled HIV infected patients from a HIV/AIDS reference Center in southern Brazil. Metabolic syndrome was identified according to the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP-ATPIII), the International Diabetes Federation (IDF) and the American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) criteria, and using a standardized questionnaire and blood testing.

Results

A sample of 1240, out of 1295, HIV-infected patients was enrolled. Males were on average older, more educated, and had shorter time since the HIV diagnosis. The population attributable risk (PAR) for waist circumference explained 80% of the prevalence among men and women (AHA/NHLBI criteria). Triglycerides had the highest impact on prevalence of metabolic syndrome according to all criteria, independently of age, skin color and HAART use, among men.

Conclusions

In this large sample of HIV infected patients, the overall prevalence of metabolic syndrome, under either classification, was noticeable and the AHA/NHLBI definition accounted for the highest prevalence.

【 授权许可】

   
2012 Alencastro et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28:1769-1778.
• [2]Lorenzo C, Williams K, Hunt KJ, Haffner SM: The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007, 30:8-13.
• [3]Hall WD, Watkins LO, Wright JT Jr, Wenger NK, Kumanyika SK, Gavin JR 3rd, Ferdinand KC, Watson K, Clark LT, Flack JM, Reed JW, Horton EW, Saunders E, African-American Lipid and Cardiovascular Council: The metabolic syndrome: recognition and management. Dis Manag 2006, 9:16-33.
• [4]Alberti KG, Zimmet P, Shaw J: The metabolic syndrome–a new worldwide definition. Lancet 2005, 366:1059-1062.
• [5]Adult Treatment Panel III: Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Publication 01-3670. National Institutes of Health, Bethesda,MD; 2002:1-50. NIH Publication No. 02-5215
• [6]Adult Treatment Panel III: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
• [7]The International Diabetes Federation: The IDF consensus worldwide definition of metabolic syndrome [article online]. 2005. In: http://www.idf.org/webdata/docs/MetS_def_update2006.pdf webcite
• [8]Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
• [9]Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
• [10]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes Federation TaskForce on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; InternationalAtherosclerosis Society; International Association for the Study of Obesity: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
• [11]Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
• [12]Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care 2004, 27:2444-2449.
• [13]Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A: Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007, 30:113-119.
• [14]Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, Cordier L, Pusterla L, Bombelli M, Sega R, Quirino T, Mancia G: HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr 2007, 45:426-431.
• [15]Grinspoon SK: Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005, 118(Suppl 2):23S-28S.
• [16]Nolan D: Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003, 63:2555-2574.
• [17]Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood PressureEducation Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
• [18]SBC: I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica. Arq Bras Cardiol 2005, 84(1):S1-S28.
• [19]O’Brien E, Mee F, Atkins N, Thomas M: Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Press Monit 1996, 1:55-61.
• [20]World Health Organization: Physical status: the use and interpretation of anthropometry. Report of the WHO Expert Committee. World Health Organ Tech Rep Ser 1995, 854:1-452.
• [21]Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
• [22]Bucolo G, David H: Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973, 19:476-482.
• [23]Trinder P: Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 1969, 22:158-161.
• [24]PN/DST/AIDS: Ministério da Saúde do Brasil - Programa Nacional de Doenças Sexualmente Transmissíveis / AIDS - Rede Nacional de Labortórios de CD4+/CD8+ e de Carga Viral. 2009. In: http://www.aids.gov.br/data/ webcite
• [25]Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Dubrow R, Rotterdam H, West AB, Blaser M, Blot WJ, Gail MH, Fraumeni JF Jr: Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003, 95:1404-1413.
• [26]Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 2004, 364:937-952.
• [27]Levine B: What does the population attributable fraction mean? Prev Chronic Dis 2007, 4:A14.
• [28]Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN: Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989, 86:27-31.
• [29]Meenan J, Mooney E, Mosquita N, Johnson AH, Collins P, Feely J, Mulcahy FM: The impact of HIV disease progression on serum lipoproteins. AIDS 1992, 6:1551-1552.
• [30]Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, Wanke C: Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006, 43:458-466.
• [31]Squillace N, Zona S, Stentarelli C, Orlando G, Beghetto B, Nardini G, Esposito R, Guaraldi G: Detectable HIV Viral Load Is Associated With Metabolic Syndrome. J Acquir Immune Defic Syndr 2009, 52:459-464.
• [32]Hansen BR, Petersen J, Haugaard SB, Madsbad S, Obel N, Suzuki Y, Andersen O: The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy. HIV Med 2009, 10:378-387.
• [33]Bonfanti P, Ricci E, de Socio G, Zeme D, Carradori S, Penco G, Parruti G, Grosso C, Madeddu G, Vichi F, Bini T, Martinelli C, Melzi S, Quirino T, CISAI StudyGroup: Metabolic syndrome: a real threat for HIV-positive patients?: Results from the SIMONE study. J Acquir Immune Defic Syndr 2006, 42:128-131.
• [34]Gus M, Cichelero FT, Moreira CM, Escobar GF, Moreira LB, Wiehe M, Fuchs SC, Fuchs FD: Waist circumference cut-off values to predict the incidence of hypertension: an estimation from a Brazilian population-based cohort. Nutr Metab Cardiovasc Dis 2009, 19:15-19.
• [35]Donato GB, Fuchs SC, Oppermann K, Bastos C, Spritzer PM: Association between menopause status and central adiposity measured at different cutoffs of waist circumference and waist-to-hip ratio. Menopause 2006, 13:280-285.
• [36]Athyros VG, Ganotakis ES, Tziomalos K, Papageorgiou AA, Anagnostis P, Griva T, Kargiotis K, Mitsiou EK, Karagiannis A, Mikhailidis DP: Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin 2010, 26:713-719.
• [37]Panagiotakos DB, Pitsavos C, Das UN, Skoumas Y, Stefanadis C: The implications of anthropometric, inflammatory and glycaemic control indices in the epidemiology of the metabolic syndrome given by different definitions: a classification analysis. Diabetes Obes Metab 2007, 9:660-668.
• [38]Ascaso JF, Romero P, Real JT, Lorente RI, Martinez-Valls J, Carmena R: Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med 2003, 14:101-106.
• [39]Bernal E, Masia M, Padilla S, Martin-Hidalgo A, Gutierrez F: Prevalence and characteristics of metabolic syndrome among HIV-infected patients from a Mediterranean cohort]. Med Clin (Barc) 2007, 128:172-175. quiz 171 p following 200
• [40]Jerico C, Knobel H, Montero M, Ordonez-Llanos J, Guelar A, Gimeno JL, Saballs P, López-Colomés JL, Pedro-Botet J: Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005, 28:132-137.